basic information
mesothelioma & asbestos
mesothelioma treatment
mesothelioma research

mesothelioma cancer
malignant mesothelioma
peritoneal mesothelioma
pleural mesothelioma
malignant pleural mesothelioma

picking an attorney
mesothelioma lawyers
settlement examples
asbestos litigation
abuse of lawsuits

news articles
clinical research







Mesothelioma Clinical Trials

Treatment of Peritoneal Cancer with Surgery, Perfused Heated Cisplatin, and Chemotherapy

This study is currently recruiting patients.

Sponsored by

For more information:National Cancer Institute (NCI)

This study will test the effectiveness of an experimental treatment for peritoneal cancer involving surgical removal of the tumor, perfusion of the abdomen during surgery with a heated solution of the drug cisplatin, and post-surgery combination chemotherapy.

Patients with peritoneal cancer whose tumor is confined to the abdomen may be eligible for this study. Candidates will be screened with a medical history and physical examination including blood tests, electrocardiogram, and possibly bone scan, brain magnetic resonance imaging, and chest, abdomen and pelvic CT scans. Those enrolled in the study will undergo surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected. During surgery, after the tumor has been removed, two catheters (thin plastic tubes) will be placed in the abdomen. A chemotherapy solution containing the anti-cancer drug cisplatin heated to a temperature of about 108.6 degrees (10 degrees above normal body temperature) will then be delivered into the abdomen through one catheter and drained through another. After 90 minutes of bathing the abdomen with this solution, the drug will be rinsed from the abdomen and the catheters removed. Another small catheter will then be placed and left inside the abdomen with one end coming out through the skin. Two to 10 days after the operation, the drugs fluorouracil (5-FU) and paclitaxel will be given through this catheter.

After complete recovery from the surgery, the catheter will be removed and the patient discharged from the hospital. Clinic visits will be scheduled for periodic follow-up examination and tests.

Patients in this study will also be asked to assess how this therapy affects their general health and well being. This will require filling out two quality-of-life questionnaires before surgery and again at each follow-up visit after surgery. Each questionnaire takes about 15 minutes to complete.

Condition Treatment or Intervention
Abdominal Neoplasm
Colonic Neoplasm
Peritoneal Neoplasm

This is a Phase II test

  • In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.  

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) with Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis

Further Study Details: 

Cytoreductive surgery plus aggressive combination intraperitoneal chemotherapy may significantly alter the natural history of peritoneal carcinomatosis. The purpose of this study is to examine the treatment results of continuous hyperthermic peritoneal perfusion with cisplatin plus early postoperative intraperitoneal dwell therapy with 5-FU and paclitaxel after cytoreductive surgery for peritoneal carcinomatosis. Results will be assessed by following the time to radiographic or clinical recurrence of disease and survival. Patients will be stratified for entry based on histology. This will include 3 cohorts: 1) peritoneal mesothelioma; 2) low grade mucinous adenocarcinoma (including low grade mucinous neoplasms of borderline malignant potential); and 3) adenocarcinoma of gastrointestinal origin (other than low grade mucinous).

Genders Eligible for Study:  Both


The patient must have histologically proven peritoneal carcinomatosis from the following histologies: primary peritoneal mesothelioma; low grade mucinous adenocarcinoma (including low grade mucinous neoplasms of borderline malignant potential); adenocarcinoma of gastrointestinal tract origin (other than low grade mucinous, excluding pancreatic cancer).
Radiologic workup must demonstrate that the disease is confined to the peritoneal cavity.
Radiologic workup or prior abdominal exploration must be consistent with disease which can be debulked to a residual size of less that 1 cm in diameter per tumor deposit.
Patients must have an ECOG performance status of less than or equal to 2.
Patients must have a minimum expected duration of survival of greater than 8 weeks.
Patients must have recovered from any toxicity from all prior chemotherapy, immunotherapy or radiotherapy and be at least 30 days past the date of their last treatment.
Patients will be excluded if they have concomitant medical problems that would place them at unacceptable risk for a major surgical procedure.
Patients at increased risk for coronary artery disease or cardiac dysfunction (e.g., age greater than 65, history of hypertension, first degree relative with atherosclerotic coronary artery disease) will undergo cardiac evaluation and will not be eligible if they demonstrate significant irreversible ischemia on a stress thallium study or an injection fraction of less than 40%.
Patients who have shortness of breath with minimal exertion and who are at risk for pulmonary disease (e.g., chronic smokers) will undergo pulmonary function testing and will not be eligible if their FEV1 is less than 1.2 liters or their maximum voluntary ventilation is less than 50% of expected.
Patients who have a baseline neurological toxicity of Grade 3 or greater will be excluded because of the potential neurotoxicity associated with platinum and paclitaxel therapy.
Patients will be ineligible if they have a creatinine of greater than 1.5 or a creatinine clearance of less 70 mL/min.
Patients will be ineligible if the WBC is less than 3000/microliters or platelets are less than 75,000/mm(3).
Patients will be ineligible if the serum total bilirubin level or liver enzymes are greater than 2 times the upper limit of normal.
Patients who have failed previous intraperitoneal platinum therapy will be ineligible. Treatment failure is defined as radiographic evidence of disease progression on two consecutive CT scans within 6 months of treatment.
Pregnant women or women who are breast feeding will be ineligible.
Patients less than 30 kg will be ineligible.


Privacy    Terms of Use & Copyright    Home   

Contact Us